Latest Us Market Expansion News

Artrya Limited marked its first full year of US commercial operations with a $25.18 million loss, driven by regulatory clearances, customer contracts, and an $80 million capital raise.

ReNerve Ltd (ASX:RNV) reported an 80% year-on-year revenue increase in Q4 FY26, backed by expanding product lines and a $5 million funding facility. The company is advancing FDA approvals and growing its global distribution footprint, targeting a rapidly expanding $6.19 billion nerve repair biomaterials market.

InFocus Group Holdings has rolled out a major upgrade to its Codexa sweepstakes casino platform, introducing a VIP-style player experience and a proprietary AI-driven compliance engine designed to streamline operations and reduce costs for white-label operators.

Metallium Limited has appointed key board members and executives to strengthen governance and operational capacity as it advances its Flash Joule Heating technology towards commercialisation in the US.

Imricor Medical Systems has ignited its US commercial operations with rapid adoption by top pediatric hospitals, buoyed by FDA pediatric clearances and clinical trial progress.

Acusensus has landed a statewide contract in Kentucky to provide real-time speed enforcement at highway work zones, with initial orders worth US$2.1 million and potential expansion to US$20 million over five years.

Ava Risk Group has appointed Bryant Henson as CEO to spearhead its next growth phase, with a sharp focus on expanding its footprint in the United States and strengthening commercial execution worldwide.

Metallium has validated its Flash Joule Heating technology through extensive testing and multi-reactor operation, advancing towards commercial e-waste processing at its Texas campus in H1 2027.

Peak Processing (ASX: PKP) has recorded its first positive Group EBITDA quarter, driven by record beverage production and a significant US manufacturing agreement, marking a pivotal turnaround in FY26.

PainChek lifted implemented ARR by 5.9% to $4.46 million and secured its first US commercial contracts under a major Sabra REIT agreement, boosting customer receipts 27% in the June quarter.

Cyclopharm’s Technegas® has been named the preferred ventilation agent in new US lung imaging guidelines, marking the first update in 14 years and potentially accelerating adoption across American hospitals.

Vitrafy Life Sciences has partnered with the historic Hoxworth Blood Center to deploy its next-generation cryopreservation technology, aiming to address a critical gap in red blood cell preservation ahead of legacy technology discontinuation in 2027.